Holen Sie sich die Stockscreener-App
55.41
0.45%
0.25
Vorhandelsmarkt:
55.49
0.08
+0.14%
Schlusskurs vom Vortag:
$55.16
Offen:
$55.1
24-Stunden-Volumen:
377.39K
Relative Volume:
1.08
Marktkapitalisierung:
$1.13B
Einnahmen:
$1.77M
Nettoeinkommen (Verlust:
$-123.74M
KGV:
-6.0425
EPS:
-9.17
Netto-Cashflow:
$-95.21M
1W Leistung:
+6.78%
1M Leistung:
+30.87%
6M Leistung:
-30.38%
1J Leistung:
-3.01%
1-Tages-Spanne:
$53.88
$55.99
1-Wochen-Bereich:
$51.48
$59.10
52-Wochen-Spanne:
$26.70
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Vergleichen Sie PRAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
55.41 | 1.06B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
Praxis Precision Medicines Inc. Stock Analysis and ForecastFree Risk Assessment Services - Autocar Professional
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
What drives Praxis Precision Medicines Inc. stock priceConsistent triple-digit returns - jammulinksnews.com
Major Depressive Disorder Clinical Trials, Companies, - openPR.com
Is Praxis Precision Medicines Inc. a good long term investmentDynamic investment opportunities - jammulinksnews.com
Does Praxis Precision Medicines Inc. stock pay reliable dividendsShort Squeeze Radar - Newser
Why Praxis Precision Medicines Inc. stock attracts strong analyst attentionGroup Only Stock Signals - Newser
What analysts say about Praxis Precision Medicines Inc. stockConsistent high-yield stocks - Autocar Professional
Praxis Precision Medicines’ (PRAX) Buy Rating Reiterated at HC Wainwright - Defense World
(PRAX) Trading Report - news.stocktradersdaily.com
Here's Why We're Not Too Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Situation - 富途牛牛
Praxis Precision Medicines stock gets BTD for relutrigine, H.C. Wainwright maintains Buy - Investing.com Nigeria
Praxis Precision Medicines stock gets BTD for relutrigine, H.C. Wainwright maintains Buy By Investing.com - Investing.com South Africa
PRAX: HC Wainwright & Co. Reiterates Buy Rating with $105 Target - GuruFocus
Praxis Precision gets FDA breakthrough therapy status for Relutrigine - Seeking Alpha
FDA grants breakthrough therapy designation to Praxis’ relutrigine for pediatric epilepsy - Investing.com Canada
Q1 Earnings Forecast for PRAX Issued By HC Wainwright - Defense World
Praxis Precision Medicines and the Breakthrough Potential of Relutrigine in Rare Epilepsy Therapies: Strategic and Financial Implications of FDA Breakthrough Therapy Designation - AInvest
Praxis Says FDA Grants Breakthrough Therapy Designation To Relutrigine For Rare Pediatric Epilepsies - Nasdaq
FDA grants breakthrough therapy status to Praxis’s relutrigine By Investing.com - Investing.com Canada
FDA grants breakthrough therapy status to Praxis’s relutrigine - Investing.com Australia
Praxis Precision Medicines Gains FDA Breakthrough Designation - TipRanks
PRAX Gains FDA Breakthrough Designation for Pediatric Epilepsy D - GuruFocus
Praxis Precision Medicines Receives Breakthrough Therapy Designation for Relutrigine in Pediatric Developmental and Epileptic Encephalopathies - Quiver Quantitative
Praxis Precision Medicines Receives FDA Breakthrough - GlobeNewswire
Praxis's Rare Epilepsy Drug Achieves FDA Breakthrough Status: 90% Seizure Reduction in Trial Patients - Stock Titan
How Praxis Precision Medicines Inc. stock performs during market volatilityLow Drawdown Trade Signals - Newser
What makes Praxis Precision Medicines Inc. stock price move sharplySwing Trade Signals - Newser
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):